TrialBlood cancer journal2024

Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study.

Yi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.